Novartis Says FDA Approved Branded Copy of Sanofi’s Jevtana Drug

Novartis AG’s Sandoz unit won final approval of its branded copy of Sanofi’s Jevtana on Thursday, less than a week before their bench trial in Delaware over allegations it infringes a patent for the prostate cancer treatment.

Sandoz also proposed an expedited post-trial briefing schedule that would wrap up by the end of February, according to a letter sent to Judge Richard G. Andrews on Friday in the US District Court for the District of Delaware.

A bench trial is scheduled to begin Jan. 11, with closing arguments set for Jan. 13.

Sandoz is the last remaining generic-drug maker in ...